The FDA has issued its approval on a new drug aimed at treating the inhalation of anthrax. The new drug, called Anthrasil, is an antibacterial aimed specifically at anthrax and tested well in various clinical trials on animals. No human trials were conducted. Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, released a statement about the new drug approval.
The FDA has issued approval to a new breast cancer drug called Ibrance (palbociclib). The new Pfizer product is specifically for use in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer and inhibits molecules that enable tumor growth.